Disparities and Inequities in the Diagnosis and Care of Vulnerable Patient Populations
b'Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
\\n\\n\\n \\n
New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive impairment (MCI) and early-onset Alzheimer\\u2019s disease (AD). The FDA has recently approved new disease-modifying therapies (DMTs) that slow the clinical course of MCI caused by AD. This curriculum helps clinicians identify the subtle signs and symptoms of MCI in AD. The program also helps clinicians recognize why and how racial and ethnic differences and disparities affect DMT acceptance, patient outcomes, and disease onset and progression. Faculty discuss the emerging data surrounding the novel pathways and mechanisms that drive MCI in AD and outline evidence-based treatment strategies as well as how to incorporate the new DMTs into clinical practice.
'